Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Albano, Francesco ^a   Zagaria, Antonella ^a   Anelli, Luisa ^a   Coccaro, Nicoletta ^a   Impera, Luciana ^a   Minervini, Crescenzio Francesco ^a   Minervini, Angela ^a   Rossi, Antonella Russo ^a   Tota, Giuseppina ^a   Casieri, Paola ^a   Specchia, Giorgina ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cellular pathways; Chronic myeloid leukemia; Gene expression profiling; Protein kinases; Variant t(9; 22) rearrangements

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 2 BETA; TRIBBLES HOMOLOG 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; SIGNAL TRANSDUCTION;

EID: 84876973525     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-36     Document Type: Article

References (14)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464. 10.1056/NEJMra020777, 14534339.
2. Melo JV, Barnes DJ. Chronic myeloid leukemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453. 10.1038/nrc2147, 17522713.
3. Mitelman F, Johansson B, Mertens F. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer 2012, http://www.cgap.nci.nih.gov/Chromosomes/Mitelman.
4. Zagaria A, Anelli L, Albano F, Storlazzi CT, Liso A, Roberti MG, Buquicchio C, Liso V, Rocchi M, Specchia G. A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. Cancer Genet Cytogenet 2004, 150:81-85. 10.1016/j.cancergencyto.2003.08.018, 15041230.
5. Landstrom AP, Tefferi A. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma 2006, 47:397-402. 10.1080/10428190500353133, 16396761.
6. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001, 98:1732-1738. 10.1182/blood.V98.6.1732, 11535505.
7. Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Rossi AR, Vicari L, Liso V, Rocchi M, Specchia G. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol Cancer 2010, 9:120. 10.1186/1476-4598-9-120, 2887383, 20500819.
8. Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G, Testoni N. Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood 2011, 117:6793-6800. 10.1182/blood-2011-01-328294, 21447834.
9. Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res 2012, 18(4):930-937. 10.1158/1078-0432.CCR-10-1613, 22156549.
10. Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T. Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood 2010, 116:2768-2775. 10.1182/blood-2009-10-246264, 20610816.
11. Dougherty CJ, Kubasiak LA, Frazier DP, Li H, Xiong WC, Bishopric NH, Webster KA. Mitochondrial signals initiate the activation of c-Jun N-terminal kinase (JNK) by hypoxia-reoxygenation. FASEB J 2004, 18:1060-1070. 10.1096/fj.04-1505com, 15226266.
12. Cao Q, McIsaac SM, Stadnyk AW. Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway. Am J Physiol Cell Physiol 2012, 302:C1731-C1740. 10.1152/ajpcell.00213.2011, 22496247.
13. Villuendas R, Steegmann JL, Pollán M, Tracey L, Granda A, Fernández-Ruiz E, Casado LF, Martínez J, Martínez P, Lombardía L, Villalón L, Odriozola J, Piris MA. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006, 20:1047-1054. 10.1038/sj.leu.2404197, 16598311.
14. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799. 10.1073/pnas.0510423103, 1413797, 16477019.